Novel Biologic Therapies for Second-Line Gastric Cancer Charles S. Fuchs, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA.
Selezione dei pazienti affetti da melanoma Vanna Chiarion Sileni Melanoma and Skin Cancer Unit IOV-IRCCS, Padova.
Updated Safety Data from a Randomized Phase 2 Trial of Hedgehog Pathway Inhibitor GDC-0449 vs. Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients.
Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF
No Effect on Tumor Response with Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in locally Advanced Rectal Cancer Ali Shamsedddine, MD Professor.
Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR.
Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.
Johanna Bendell, MD Director, GI Oncology Research Associate Director, Drug Development Unit
Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division
ABSTRACT
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
1 ODAC September 13 th, 2005 Tarceva ® (erlotinib) Adrian Senderowicz, M.D. DDODP, CDER FDA.
